|
 |
Volume 1, Number 1 (May/June 2004) | |||||
Letter from the Editor |
|||||
11 |
Why we created this new journal The West Clinic, Memphis, TN There is a clear-cut need for a journal focused specifically on the way community oncologists actually practice, offering vital, useful, clinically relevant, and timely information for a rapidly changing and complex environment.
|
||||
Community Translations |
|||||
15 |
Chemotherapy of advanced colorectal cancer Interpreting the pivotal FOLFOX, FOLFIRI, and IROX trials
|
||||
19 |
Aromatase inhibitors as adjuvant therapy for early-stage breast cancer What we have learned from ATAC and other recent clinical trials
|
||||
Original Research |
|||||
23 |
Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice The West Clinic and Supportive Oncology Services, Inc., Memphis, TN Implementing strategies to lessen the number of visits needed to manage chemotherapy-induced neutropenia can reduce human resource time and costs and help focus these resources on other treatment-related activities.
|
||||
Economics/Practice Management |
|||||
30 |
Cancer in America, 2004 Wilshire Medical Oncology Group, Inc., La Verne, CA, and University of California, San Francisco Improvements in cancer outcomes achieved over the past 3 decades have also resulted in increased costs for cancer care, a burden that is increasingly being shouldered by patients and their physicians. Community oncologists can help reverse this trend by developing ways to link reimbursement with actual costs, introducing greater efficiencies in their practice, and raising their profile by educating the public through more effective use of the media.
|
||||
Community Dialogue |
|||||
36 |
Clinical trials in community practice: private practitioner networks can help Arena Oncology Associates is 1 of 15 community oncology practices that are participating in the Accelerated Community Oncology Research Network (ACORN), an organization dedicated to helping its member practices engage in clinical studies. Dr. Arena and his colleagues hope the ACORN model could serve as a prototype for other community oncology practices that lack the staff or otherwise hesitate to participate in clinical trials.
|
||||
Technology |
|||||
40 |
AnalyzeIt—software that provides the true costs of regimens and services by CPT codes Cancer Specialists of Tidewater, Ltd., Chesapeake, VA AnalyzeIt is a cost-management and analysis software program for group and community oncology practices. It can accurately determine the costs of various treatment regimens, calculate the expected reimbursements from any of the practice’s payers, identify missed drug billings, and provide reports linking insurance reimbursement rates to actual expenses.
|
||||
Rare Cancers |
|||||
47 |
Malignant paraganglioma Wilshire Medical Oncology Group, Inc., La Verne, CA, and University of California, San Francisco This case of a 43-year-old man with a rare metastatic paraganglioma illustrates the myriad issues and challenges faced by physician, staff, patient, family, consultants, lawyers, and insurers in developing and implementing a complex treatment plan. The methods used to achieve a successful outcome for this patient are discussed, plus suggested newer approaches that might improve care for patients with this and other rare cancers.
|
||||
Meetings Highlights & Calendar |
|||||
53 |
‘Prepare now for the new Medicare bill’ says this consultant
|
53 |
Attorney urges healthcare providers to stay informed about anti-kickback laws
| ||
54 |
Meetings Calendar |
||||
Legislative Update |
|||||
59 |
Problems facing cancer care with Medicare’s definition of average selling price Community Oncology Alliance Why the Medicare cancer care drug reimbursement system based on the average selling price of cancer drugs needs to be addressed and fixed before January 1, 2005
| ||||
59 |
Need to reach out to Congress is critical
|
||||
Reader Services |
|||||
4 |
Guide for Authors
| ||||
56 |
Community Classifieds
|
||||
© 2004 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
|||||
64 kb